Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|
All Comparisons

MOTS-c vs AOD-9604

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

MOTS-c: DAOD-9604: C
AttributeMOTS-cAOD-9604
CategoryMetabolic / MitochondrialMetabolic / Fat Loss
Evidence RatingDPreclinicalCPhase I–II Clinical Trials
Clinical StatusResearch-only / No human clinical trials completed (Phase 1 of analog CB4211 only)Clinical development discontinued after Phase 2; GRAS status for food use
MechanismMOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis. Under stres...AOD-9604 (C78H123N23O23S2) works through a dual-action mechanism: it accelerates breakdown of stored fat (lipolysis) via cAMP signaling and enzymatic activation (stimulating hormone-sensitive lipase), while simultaneously blocking formation of new fat (lipogenesis). It stimulates lipolysis in a mann...
Half-LifeSeveral hours; tissue effects may persist longer~30 minutes
Bioavailability
Molecular Weight~2174.6 g/mol~1815.1 g/mol
WADA StatusNot ListedProhibited
Dosing5–10 mg SC per injection, Once daily or 3–5x weekly (Subcutaneous)250–500 mcg/day SC, Once daily (Subcutaneous)
Key Use Cases
  • Metabolic Health
  • Anti-Aging
  • Fat Loss
Safety Concerns
  • No adverse effects reported in preclinical animal studies
  • Human tolerability is completely unknown for native MOTS-c (no completed human trials)
  • Modified analog CB4211 showed good tolerability in Phase 1
  • In extensive clinical trials, side effect profile was virtually indistinguishable from placebo
  • Mild injection site reactions (redness, pain, small welts) are the most common complaint
  • Mild headaches or flushing reported in small percentage of users
Contraindications
  • No established contraindications due to absence of human clinical data
  • Caution in diabetics on glucose-lowering medication (potential additive hypoglycemia based on mechanism)
  • Pregnancy and breastfeeding (no data)
  • Active cancer (AMPK modulation has complex effects on tumor biology)
  • Active cancer (while AOD-9604 does not stimulate IGF-1, any metabolic modulator should be used with extreme caution in malignancy)
  • Pregnancy and breastfeeding (no safety data)
  • Children and adolescents (interfering with fat metabolism during puberty not recommended)
Regulatory (US)Not FDA-approved. Removed from FDA Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026. Research chemical.Not FDA-approved as a drug. FDA granted GRAS status for food use (2014). Available as research chemical.

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.